Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameVenus Medtech-B
Stock Code02500
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities按二零一八年植入量計,為中國領先的經導管心臟瓣膜醫療器械企業,主要從事經導管心臟瓣膜產品的設計、開發及商業化,產品涵蓋主動脈瓣、肺動脈瓣、二尖瓣及三尖瓣的經導管解決方案及主要配套產品。
Listing Date2019-12-10
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國杭州濱江區江陵路88號2幢3樓311室
Business Address (Hong Kong)香港灣仔皇后大道東248號陽光中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.venusmedtech.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 33.00 / shares
Offer Price RangeTo be extracted
Lot Size500 shares
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2019-11-28 to 2019-12-03
Global Offering Shares78,537,500 shares
HK Public Offer Shares (Initial)7,854,000 shares (10.0%)
Public Offer Lots (Initial)15,708lots (Pool A7,854lots,Pool B7,854lots)
International Placing Shares (Initial)70,683,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO392,688,443 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share39.3%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 2,591,737,500

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 694.9M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +1298%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣300.5百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 USD
Income Statement
Item 20172018
Other income and gains, net 076
Selling and distribution expenses -1,764-1,625
Administrative expenses -3,042-7,070
Net finance costs -676-945
Profit before tax -19,261-22,601
Income tax expense -37-144
Profit for the year -19,298-22,745
Profit attributable to owners -19,298-22,745
Balance Sheet
Item 201720182019-05
Cash and cash equivalents 1,1457,279
Inventories 00
Total current assets 1,4977,607
Total current liabilities 4,4589,332
Total equity -5,960-812
Equity attributable to owners -5,960-812
Interest-bearing borrowings 5,22000
Cash Flow Statement
Item 20172018-0520182019-05
Net cash from operating activities -16,158-14,093
Net cash from investing activities -115-30
Net cash from financing activities 8,99920,257
Net increase in cash -7,2746,134
Depreciation of PP&E 93287019
Depreciation of right-of-use assets 21085210100
Purchase of PP&E -1150-30-23
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 43.05
First Day OpenHK$ 40.0
First Day Change30.45%
First Day Volume53035200.0
First Day Turnover2107270000.0
Use of Proceeds
1、35.0%或約843.9百萬港元分配至我們的核心產品; 2、30.0%或約723.3百萬港元分配至我們的其他產品及在研產品; 3、10.0%所得款項凈額或約241.1百萬港元,為有關收購Keystone的代價付款及其他交易開支提供資金; 4、15.0%所得款項凈額或約361.7百萬港元,為我們透過內部研究及/或潛在收購持續擴充產品組合提供資金; 5、10.0%所得款項凈額或約241.1百萬港元,作營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Overall Coordinators (6)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 招银国际融资有限公司 CE AVM940 海通国际证券有限公司 CE AAF806
Joint Bookrunners (9)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 招银国际融资有限公司 CE AVM940 海通国际证券有限公司 CE AAF806 BOCI ASIA LIMITED CE AET863 农银国际融资有限公司 CE AWL249 香港上海汇丰银行有限公司 CE AAA523
Joint Lead Managers (9)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 招银国际融资有限公司 CE AVM940 海通国际证券有限公司 CE AAF806 BOCI ASIA LIMITED CE AET863 农银国际证券有限公司 CE ACX411 香港上海汇丰银行有限公司 CE AAA523

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Aspex Master Fund 156,519,000 HKD — 6.04% — 6 months 2020-06-10
2 Cephei QFII China Total Return Fund Ltd. 156,519,000 HKD — 6.04% — 6 months 2020-06-10
3 China Alpha Funds 78,259,500 HKD — 3.02% — 6 months 2020-06-10
4 GIC Private Limited 234,778,500 HKD — 9.06% — 6 months 2020-06-10
5 Hillhouse Funds 391,297,500 HKD — 15.10% — 6 months 2020-06-10

Directors & Management

PositionChinese nameEnglish Name
Chairman曾敏—
Company Secretary馬海越、霍寶兒—
No director data available.

Major Shareholders

Major Shareholders & Holdings訾先生實益擁有30,923,302股內資股(7.87%),另通過受控法團持有14,894,971股內資股(3.79%)及11,057,251股非上市外資股(2.82%);曾先生通過Horizon Binjiang LLC持有47,954,404股非上市外資股(12.21%)。Qiming相關實體合計持有30,342,501股H股(17.75%)及37,185,479股非上市外資股(16.77%)。
About this page

This page shows Venus Medtech-B (02500) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect